Fukazawa H, Yoshida K, Kaise N, Kiso Y, Sayama N, Mori K, Kikuchi K, Aizawa Y, Rikimaru A, Abe K
National Narugo Hospital, Japan.
Thyroid. 1995 Oct;5(5):373-7. doi: 10.1089/thy.1995.5.373.
Intercellular adhesion molecule (ICAM-1), a ligand for lymphocyte function-associated antigen-1 (LFA-1), plays an important role in a variety of immune-mediated mechanisms such as lymphocyte attachment to cultured Graves' thyroid cells. We report the detection of a soluble form of the ICAM-1 molecule (sICAM-1) in sera from patients with Graves' disease (GD) and other thyroid disorders. The mean (+/- SD) sICAM-1 concentration in 28 euthyroid control subjects was 1931 +/- 681 pmol/L. The mean sICAM-1 concentration in 25 untreated hyperthyroid patients with GD was significantly elevated (3065 +/- 890 pmol/L), and decreased significantly (2489 +/- 845 pmol/L) after treatment with antithyroid drugs and/or 131I. Of 14 GD patients who had been in remission following administration of antithyroid drugs, 12 had recurrent disease. In 10 of the 12 patients in whom GD recurred, the sICAM-1 concentration (3807 +/- 796 pmol/L) increased significantly. The mean sICAM-1 concentration in patients with hypothyroidism due to chronic thyroiditis (n = 15:2895 +/- 569 pmol/L) was significantly elevated over that of control subjects, and not different from untreated hyperthyroid patients. The mean sICAM-1 concentration in patients with subacute thyroiditis (n = 13: 3036 +/- 441 pmol/L) was significantly elevated, while the mean sICAM-1 concentration in patients with nodular goiter (n = 10: 2318 +/- 490 pmol/L) was within the normal range. These results indicate that mean serum sICAM-1 concentration was significantly elevated in patients with untreated GD, and it decreased after treatment and increased at the time of recurrence. Therefore, the elevated serum concentration of sICAM-1 in patient with GD probably reflects ongoing immune processes.
细胞间黏附分子（ICAM-1）是淋巴细胞功能相关抗原-1（LFA-1）的配体，在多种免疫介导机制中发挥重要作用，如淋巴细胞与培养的格雷夫斯甲状腺细胞的附着。我们报告了在格雷夫斯病（GD）患者和其他甲状腺疾病患者的血清中检测到可溶性ICAM-1分子（sICAM-1）。28名甲状腺功能正常的对照受试者的平均（±标准差）sICAM-1浓度为1931±681 pmol/L。25名未经治疗的GD甲亢患者的平均sICAM-1浓度显著升高（3065±890 pmol/L），在用抗甲状腺药物和/或131I治疗后显著降低（2489±845 pmol/L）。在14名服用抗甲状腺药物后缓解的GD患者中，有12名复发。在复发的12名患者中的10名中，sICAM-1浓度（3807±796 pmol/L）显著升高。慢性甲状腺炎所致甲状腺功能减退患者（n = 15：2895±569 pmol/L）的平均sICAM-1浓度显著高于对照受试者，与未经治疗的甲亢患者无差异。亚急性甲状腺炎患者（n = 13：3036±441 pmol/L） 的平均sICAM-1浓度显著升高，而结节性甲状腺肿患者（n = 10：2318±490 pmol/L）的平均sICAM-1浓度在正常范围内。这些结果表明，未经治疗的GD患者血清sICAM-1平均浓度显著升高，治疗后降低，复发时升高。因此，GD患者血清sICAM-1浓度升高可能反映了正在进行的免疫过程。
